New possibilities of «old» antibiotics: high-dose Amoxiclav in the practice of a pediatrician


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The necessity and rationality of the use of systemic antibiotics, especially in the outpatient settings, have been widely discussed in recent decades due to the growing resistance of bacterial pathogens. Antimicrobial resistance is one of the major public health problems growing due to the excessive and/or incorrect use of this group of drugs (especially systemic antibiotics) in humans and animals. Given the absence of the appearance of fundamentally new antibacterial drugs on the global pharmaceutical market, it is advisable to revise the approach to prescribing existing ones. One way is to increase the dose of the most highly effective antibiotics in modern conditions, since it has been proven, in particular, that the use of their suboptimal doses (insufficient for reliable eradication of the pathogen) leads to the selection of resistant strains. A number of antibiotics have high-dose forms, but only amoxicillin/clavulanate (both in the form of a suspension and in tablets) has been developed for the treatment of infections caused by penicillin-resistant strains of pneumococcus. This year, a new high-dose dosage form of amoxicillin/clavulanate 14:1 (Amoxiclav®) is entering the Russian pharmaceutical market. As part of the discussion of approaches to the treatment of infections of respiratory tract and ENT organs in children, taking into account the global growth of antibiotic resistance of respiratory pathogens in modern conditions, an emphasis was made on determining the place of inhibitor-protected amoxicillin with an increased content of amoxicillin and a ratio of active ingredients of 14:1 in the treatment of community-acquired infections of respiratory tract and ENT organs in children. Thus, the high-dose form of amoxicillin/clavulanate 14:1 (Amoxiclav®) can be used for the main forms of respiratory tract infection both in outpatient and inpatient pediatric practice, providing clinical and microbiological efficacy of therapy and minimizing the risk of selection of resistant strains of the main bacterial pathogens of respiratory tract infections (including ENT pathology)

全文:

受限制的访问

作者简介

E. Radzig

Pirogov Russian National Research Medical University

Email: radena@rambler.ru
Moscow, Russia

参考

  1. Богомильский М.Р. Болезни уха, горла, носа в детском возрасте: национальное руководство. Под ред. М. Р. Богомильского. 2-е изд. перераб. и доп. М.: ГЭОТАР-Медиа, 2021. 1072 с. @@Bogomilsky M.R. Ear, nose and throat diseases in childhood: a national guideline. Ed. by M.R.Bogomilsky. 2nd ed. revised and add. M.: GEOTARMedia, 2021. 1072 p. (In Russ.)
  2. Богомильский М.Р., Радциг Е.Ю., Селькова Е.П. Болезни уха, горла, носа при ОРЗ у детей. М.: ГЭОТАР-Медиа, 2016. 128 с. @@Bogomilsky M.R., Radzig E.Yu, Selkova E.P Diseases of the ear, throat, nose with acute respiratory infections in children. M.: GEOTAR-Media, 2016. 128p. (In Russ.).
  3. Septimus E.J. Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach. Med Clin North Am. 2018;102(5):819-829. Doi: 10.1016/j. mcna.2018.04.005.
  4. Clinical managementof COVID-19 Interim Guidance - May 2020. Geneva: World Health Organization; 2020. Available from: https://www.who.int/publications-detail/clinical-management-of-covid-19.
  5. Nori P, Cowman K., Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2021;42(1):84-88. doi: 10.1017/ice.2020.368.
  6. Малеев В.В. и др. «О применении антибактериальной терапии у пациентов с новой коронавирусной инфекцией COVID-19». Совместное обращение к врачебному сообществу России. Русский медицинский журнал. 17.10.2020. @@Maleev V.V. et al. «On the use of antibiotic therapy in patients with the new coronavirus infection COVID-19.» Joint appeal to the Russian medical community. Russkii meditsinskii zhurnal. 10/17/2020. (In Russ.)]. URL: https://www.rmj. ru/news/o-primenenii-antibakterialnoy-terapii-u-patsientov-s-novoy-koronavirusnoy-infektsiey-covid-19.
  7. Клинические рекомендации НМАО Острый средний отит. @@Clinical recommendations of NMAO Acute otitis media. (In Russ.)]. URL: http:// www.nmaoru.org/files/KR314%20Ostryj%20 srednij%20ot.it.pdf
  8. Клинические рекомендации НМАО Острый синусит. @@Clinical recommendations of NMAO Acute sinusitis. (In Russ.)]. URL: http://www.nmaoru.org/files/KR313%20Ostryj%20sinusit. pdf
  9. Клинические рекомендации НМАО Острый тонзиллофарингит. @@Clinical recommendations of NMAO Acute tonsillopharyngitis. (In Russ.)]. URL: http://www.nmaoru.org/files/KR306%20 Tonzillofaringit.pdf
  10. Резолюция Экспертного совета «Принципы рациональной антибиотикотерапии респи раторных инфекций у детей. Сохраним антибиотики для будущих поколений». Москва, 31 марта 2018 г Consilium Medicum. Педиатрия. 2018;3:10-15. @@Resolution of the Expert Council "Principles of rational antibiotic therapy of respiratory infections in children. We will preserve antibiotics for future generations. « Moscow, March 31, 2018. Consilium Medicum. Pediatriya. (In Russ.)]. doi: 10.26442/2413- 8460_2018.3.10-15.
  11. Mayanskiy N., Kulichenko T., Alyabieva N., et al. Changing serotype distribution and resistance patterns among pediatric nasopharyngeal pneumococci collected in Moscow, 2010-2017. Diagn Microbiol Infect Dis. 2019;94(4):385-390. doi: 10.1016/j.diagmicrobio.2019.02.010.
  12. Torumkuney D., Mayanskiy N., Edelstein M., et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia. J Antimicrob Chemother. 2018;73(suppl_5):v14-v21. doi: 10.1093/jac/dky065.
  13. Sader H.S., Flamm R.K., Streit J.M., et al. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. Int J Infect Dis. 2018;77:82-6. Doi: 10.1016/j. ijid.2018.10.004.
  14. Tomic V, Dowzicky M.J. Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008). Ann Clin Microbiol Antimicrob 2014;13:52. doi: 10.1186/s12941-014-0052-2.
  15. Cherazard R., Epstein M., Doan T.L., et al. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Ther. 2017;24(3):e361-e369. doi: 10.1097/MJT.0000000000000551.
  16. Fong I.W., Shlaes D., Drlica K. Antimicrobial Resistance Among Streptococcus pneumoniae. Antimicrobial Resistance in the 21st Century 2018. P 13-38. doi: 10.1007/978-3-319-78538-7_2.
  17. Tadesse B.T., Ashley E.A., Ongarello S., et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17(1):616. doi: 10.1186/s12879-017-2713-1.
  18. Ho J., Ip M. Antibiotic-Resistant Community-Acquired Bacterial Pneumonia. Infect Dis Clin North Am. 2019;33(4):1087-103. Doi: 10.1016/j. idc.2019.07.002.
  19. Hagiwara E., Baba T, Shinohara T., et al. Ten-Year Trends and Clinical Relevance of the Antimicrobial Resistance Genotype in Respiratory Isolates of Streptococcus pneumoniae. Chemotherapy. 2017;62(4):256-61. doi: 10.1159/000470828.
  20. Wang X., Cong Z., Huang W., et al. Molecular characterization of Streptococcus pneumoniae isolated from pediatric patients in Shanghai, China. Pediatr Pulmonol. 2020;55(8):2135-41. doi: 10.1002/ppul.24877.
  21. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2019. URL: https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2019.pdf.
  22. Craig W.A. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med. 2004;117(Suppl 3A):16S-22S. doi: 10.1016/j.amjmed.2004.07.004.
  23. Dagan R. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. Int J Infect Dis. 2003;7(Suppl 1):S21-6. doi: 10.1016/s1201-9712(03)90067-1.
  24. Dagan R. The use of pharmacokinetic/ pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media. Int J Antimicrob Agents. 2007;30(Suppl 2):S127-30. doi: 10.1016/j.ijantimicag.2007.07.039.
  25. Huttner A., Bielicki J., Clements M.N., et al. Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage. Clin Microbiol Infect. 2020;26(7):871-79. Doi: 10.1016/j. cmi.2019.11.028.
  26. Casey J.R., Block S.L., Hedrick J., et al. Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media. Drugs. 2012;72(15):1991-97. doi: 10.2165/11590320-000000000-00000.
  27. Harmes K.M., Blackwood R.A., Burrows H.L., et al. Otitis media: diagnosis and treatment. Am Fam Physician. 2013;88(7):435-40. Erratum in: Am Fam Physician. 2014;89(5):318. Dosage error in article text.
  28. Chu C.H., Wang M.C., Lin L.Y., et al. High-dose amoxicillin with clavulanate for the treatment of acute otitis media in children. Scientific World Journal. 2014;2013:965096. doi: 10.1155/2014/965096.
  29. Brink A.J., Cotton M., Feldman C., et al. Updated recommendations for the management of upper respiratory tract infections in South Africa. S Afr Med J. 2015;105(5):344-52. Doi: 10.7196/ samj.8716.
  30. Matho A., Mulqueen M., Tanino M., et al. High-dose versus standard-dose amoxicillin/ clavulanate for clinically-diagnosed acute bacterial sinusitis: A randomized clinical trial. PLoS One. 2018;13(5):e0196734. doi: 10.1371/journal. pone.0196734.
  31. Gaddey H.L., Wright M.T., Nelson T.N. Otitis Media: Rapid Evidence Review. Am Fam Physician. 2019;100(6):350-56.
  32. Hum S.W., Shaikh K.J., Musa S.S., Shaikh N. Adverse Events of Antibiotics Used to Treat Acute Otitis Media in Children: A Systematic Meta-Anaiysis. J Pediatr. 2019;215:139-143.e7. Doi: 10.1016/j. jpeds.2019.08.043.
  33. Leung A.K., Hon K.L., Chu W.C. Acute bacterial sinusitis in children: an updated review. Drugs Context. 2020;9:2020-9-3. Doi: 10.75 73/ dic.2020-9-3.
  34. Hoberman A., Dagan R., Leibovitz E., et ai. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Pediatr Infect Dis J. 2005;24(6):525-32. doi: 10.1097/01. inf.0000164794.50281.1a.
  35. Wald E.R., Nash D., Eickhoff J. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics. 2009;124(1):9-15. doi: 10.1542/peds.2008-2902.
  36. Dagan R., Hoberman A., Johnson C., et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20(9):829-37. doi: 10.1097/00006454-200109000-00002.
  37. Lieberthal A.S., Carroll A.E., Chonmaitree T., et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964-99. doi: 10.1542/peds.2012-3488.
  38. Chow A.W, Benninger M.S., Brook I., et ai.; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112. doi: 10.1093/cid/ cir1043.
  39. Pavez D., Perez R., Cofre J., et al. Recomendaciones para el diagnostico y tratamiento antimicrobiano de la rinosinusitis aguda bacteriana en pediatrfa [Recommendations for diagnosis and antimicrobial treatment of acute bacterial rhinosinusitis in pediatrics]. Rev Chilena Infectol. 2019;36(1):78-82. Spanish. Doi: 10.4067/ S0716-10182019000100078.
  40. Резолюция Экспертного совета. Клинический разбор в общей медицине. 2021;2:6-14. @@Expert Council Resolution. Klinicheskii razbor v obshcheimeditsine. 2021;2:6-14. (In Russ.)]. doi: 10.47407/kr2021.2.1.00036.
  41. Инструкция по медицинскому применению лекарственного препарата Амоксициллин Диспертаб® (таблетки диспергируемые 125 мг, 250 мг, 500 мг, 1000 мг). Производитель -АВВА РУС ОАО, № РУ ЛП-006567-131120. @@Instructions for the medical use of the drug Amoxicillin Dispertab® (dispersible tablets 125 mg, 250 mg, 500 mg, 1000 mg). Manufacturer -AVVA RUS JSC, RU No. LP-006567-131120. (In Russ.).
  42. Инструкция по медицинскому применению лекарственного препарата «Амоксициллин» (капсулы 250 мг). Производитель - АВВА РУС ОАО, РУ № ЛС-000409-270912. @@Instructions for medical use of the drug «Amoxicillin» (capsules 250 mg). Manufacturer -AVVA RUS OJSC, RU No. LS-000409-270912. (In Russ.).
  43. Инструкция по медицинскому применению лекарственного препарата «Амоксициллин» (капсулы 250 и 500 мг). Производитель -Хемофарм А.Д., Сербия, РУ № П N011641/01-270919. @@Instructions for medical use of the drug «Amoxicillin» (capsules 250 and 500 mg). Manufacturer - Hemofarm A.D., Serbia, RU P N011641/01-270919. (In Russ.).
  44. Инструкция по медицинскому применению лекарственного препарата «Амоксиклав» (порошок для приготовления суспензии для приема внутрь 600 мг+42,9 мг/5 мл). Производитель -Сандоз д.д., РУ № ЛП-006516-161020. @@Instructions for the medical use of the drug «Amoxiclav» (powder for the preparation of a suspension for oral administration 600 mg+42.9 mg/5 ml). Manufacturer-- Sandoz dd, RU No. LP-006516-161020. (In Russ.).

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##